Dermatology · Lexington, KY
NPI
1154767457
Since 2013
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2405 Harrodsburg Rd
Lexington, KY, 40504
Phone (859) 278-9492
Groups this clinician bills Medicare through
Medicare paid, 2024
$98K
2,204 services
Medicare patients, 2024
532
Average age 75
Drug cost, 2024
$1.1M
1,058 prescriptions
Company payments, 2025
$627
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James P Lagrew was code 17003 (destruction skin lesion), 705 times for 153 patients. In total James P Lagrew billed 2,204 services in 53 codes, and Medicare paid $98K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 705 | 153 | $4.47 | $3,155 |
| 99213 Office E&M - Established | Office | 358 | 295 | $55.31 | $20K |
| 17000 Destruction Skin Lesion | Office | 272 | 218 | $33.20 | $9,030 |
| 17110 Destruction Skin Lesion | Office | 200 | 175 | $65.78 | $13K |
| 99214 Office E&M - Established | Office | 182 | 159 | $76.78 | $14K |
| 11102 Skin Biopsy | Office | 149 | 138 | $54.81 | $8,167 |
| 17262 Destruction Skin Lesion | Office | 42 | 38 | $115.91 | $4,868 |
| 99204 Office E&M - New | Office | 38 | 38 | $92.39 | $3,511 |
| 11103 Skin Biopsy | Office | 31 | 25 | $34.50 | $1,070 |
| 99203 Office E&M - New | Office | 24 | 24 | $64.67 | $1,552 |
| 12032 Wound Repair - All Levels | Office | 23 | 21 | $172.73 | $3,973 |
| 17004 Destruction Skin Lesion | Office | 18 | 14 | $116.10 | $2,090 |
| 69100 Other Organ Systems | Office | 14 | 13 | $46.33 | $649 |
| 99212 Office E&M - Established | Office | 12 | 12 | $37.09 | $445 |
| 11603 Skin Lesion Excision | Office | 12 | 11 | $108.20 | $1,298 |
By year: 2022 $113K for 2,251 services; 2023 $114K for 2,287 services; 2024 $98K for 2,204 services.
Medicare prescription drug claims, 2024
In 2024, the drug James P Lagrew prescribed most often to Medicare patients was Clobetasol Propionate, with 147 prescriptions and refills. In total James P Lagrew wrote 1,058 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 147 | 155 | 89 | $5,170 |
| Doxycycline Hyclate Generic | 147 | 199 | 45 | $3,535 |
| Ketoconazole Generic | 100 | 102 | 45 | $1,286 |
| Triamcinolone Acetonide Generic | 91 | 126 | 65 | $1,440 |
| Minoxidil Generic | 81 | 191 | 25 | $888 |
| Hydrocortisone Generic | 77 | 78 | 49 | $536 |
| Dutasteride Generic | 53 | 147 | 16 | $848 |
| Valacyclovir Valacyclovir Hcl | 45 | 53 | Under 11 | $1,512 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 38 | 38 | Under 11 | $280K |
| Terbinafine Hcl Generic | 22 | 53 | 14 | $91.49 |
| Tremfya Guselkumab | 21 | 38 | Under 11 | $289K |
| Mupirocin Generic | 18 | 19 | 15 | $181 |
| Fluconazole Generic | 16 | 30 | Under 11 | $288 |
| Dupixent Syringe Dupilumab | 15 | 15 | Under 11 | $56K |
| Cosentyx (2 Syringes) Secukinumab | 14 | 14 | Under 11 | $101K |
Brand drugs: 118 claims; generic drugs: 940 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James P Lagrew $627 ($627 in general payments such as food, travel and fees) from 12 companies. The largest payer was Janssen Biotech, Inc. with $141.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 5 | $141 |
| Regeneron Healthcare Solutions, Inc. REGN | 5 | $103 |
| Abbvie Inc. ABBV | 5 | $101 |
| LNHC, Inc | 1 | $60.39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45.98 |
| Almirall LLC | 1 | $33.89 |
| Galderma Laboratories, L.P. GALD.SW | 1 | $32.23 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 1 | $29.07 |
| Mayne Pharma Commercial LLC | 1 | $28.34 |
| Genzyme Corporation SNY | 1 | $24.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.